Literature DB >> 8697660

TAP2D is associated with HLA-B44 and DR4 and may contribute to rheumatoid arthritis and Felty's syndrome susceptibility.

M C Hillarby1, E J Davies, R P Donn, D M Grennan, W E Ollier.   

Abstract

OBJECTIVES: TAP2 transporter gene polymorphisms have been ascertained in patients with rheumatoid arthritis (RA) and Felty's syndrome (FS) to determine whether particular alleles of this gene are disease associated.
METHODS: TAP2 dimorphisms at amino acid positions 379, 565 and 665 were detected using ARMS-PCR in 89 RA patients, 24 FS patients and 64 control subjects. TAP 2 alleles were assigned from these results.
RESULTS: The frequency of one particular allele, TAP2D, was increased in both RA (OR 2.6, 95% CI 1.2 - 5.8) and FS (OR 3.9, 95% CI 1.4 - 10.7). When individual amino acid polymorphisms were compared between patients and controls, isoleucine at position 379 (present in TAP2D and TAP2C) was significantly increased, indicating that this dimorphism itself may be associated with RA (OR 5.0, 95% CI 2.4 - 10.2) and FS (OR 5.0, 95% CI 1.91 - 3.2). DISCUSSION: The presence of TAP2D was greatly increased in HLA-B44/DR4 positive RA (83%) and FS (67%) patients. These frequencies were appreciably higher than in the HLA-B44/DR4 controls (11%), suggesting that linkage disequilibrium alone may not explain the increase in TAP2D frequency in patients and that this allele may represent an additional risk factor in these conditions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8697660

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  2 in total

1.  Role of HLA typing on Crohn's disease pathogenesis.

Authors:  Batool Mutar Mahdi
Journal:  Ann Med Surg (Lond)       Date:  2015-08-04

2.  Significant association between TAP2 polymorphisms and rheumatoid arthritis: a meta-analysis.

Authors:  Dongjun Dai; Yong Chen; Ping Ru; Xingyu Zhou; Jianmin Tao; Huadan Ye; Qingxiao Hong; Linlin Tang; Guanghui Pan; Danfeng Lin; Qiongyao Gong; Yuelong Lv; Leiting Xu; Shiwei Duan
Journal:  Diagn Pathol       Date:  2014-06-27       Impact factor: 2.644

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.